Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Vaccine|June 6, 2022
Thrombocytopenia after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting systemEmily Jane Woo, Rositsa B DimovaNutrition Journal|June 7, 2016
Inappropriate statistical method in a parallel-group randomized controlled trial results in unsubstantiated conclusionsRositsa B Dimova, David B AllisonJournal of Viral Hepatitis|July 3, 2020
Age- and risk factor-based serologic screening for Hepatitis C virus among an Urban, high-risk populationRositsa B Dimova, Eric Rude, Andrew H TalalJAMA|October 7, 2021
Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021Emily Jane Woo, Adamma Mba-Jonas, Rositsa B Dimova, et al.The Journal of Infectious Diseases|December 17, 2014
Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and RibavirinMarija Zeremski, Rositsa B Dimova, Samantha Benjamin, et al.The Journal of Infectious Diseases|August 4, 2016
Fibrosis Progression in Patients With Chronic Hepatitis C Virus InfectionMarija Zeremski, Rositsa B Dimova, Jaroslaw Pillardy, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 11, 2012
Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysisRositsa B Dimova, Marija Zeremski, Ira M Jacobson, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 1, 2013
IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patientsMarija Zeremski, Rositsa B Dimova, Jessy Makeyeva, et al.BMC Gastroenterology|July 4, 2014
FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis BMarija Zeremski, Rositsa B Dimova, Samantha Benjamin, et al.Journal of Addiction Medicine|February 17, 2016
Improvements in HCV-related Knowledge Among Substance Users on Opioid Agonist Therapy After an Educational InterventionMarija Zeremski, Roberto Zavala, Rositsa B Dimova, et al.Pageof 2